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Abstract  
Diabetic patients have increased likelihood of developing breast cancer. Advanced 
glycation endproducts (AGEs) underlie the pathogenesis of diabetic complications but 
their impact on breast cancer cells is not understood. This study aims to determine the 
effects of methylglyoxal-derived bovine serum albumin AGEs (MG-BSA-AGEs) on 
the invasive MDA-MB-231 breast cancer cell line. By performing cell counting, using 
wound-healing assay, invasion assay and zymography analysis, we found that MG-
BSA-AGEs increased MDA-MB-231 cell proliferation, migration and invasion 
through MatrigelTM associated with an enhancement of matrix metalloproteinase 
(MMP)-9 activities, in a dose-dependent manner. Using Western blot and flow 
cytometry analyses, we demonstrated that MG-BSA-AGEs increased expression of 
the receptor for AGEs (RAGE) and phosphorylation of key signalling protein 
extracellular signal-regulated kinase (ERK)-1/2. Furthermore, in MG-BSA-AGE-
treated cells, phospho-protein micro-array analysis revealed enhancement of 
phosphorylation of the ribosomal protein 70 serine S6 kinase beta 1 (p70S6K1), 
which is known to be involved in protein synthesis, the signal transducer and activator 
of transcription (STAT)-3 and the mitogen-activated protein kinase (MAPK) p38, 
which are involved in cell survival. Blockade of MG-BSA-AGE/RAGE interactions 
using a neutralizing anti-RAGE antibody inhibited MG-BSA-AGE-induced MDA-
MB-231 cell processes, including the activation of signalling pathways. Throughout 
the study, non-modified BSA had a negligible effect. In conclusion, AGEs might 
contribute to breast cancer development and progression partially through the 
regulation of MMP-9 activity and RAGE signal activation. The up-regulation of 
RAGE and the concomitant increased phosphorylation of p70S6K1 induced by AGEs 
may represent promising targets for drug therapy to treat diabetic patients with breast 
cancer.  
 
Key Words: Advanced glycation endproducts, diabetes, breast cancer, signalling 
pathway, methylglyoxal. 
 
Abbreviations: AGE, advanced glycation endproduct; AP, activator protein; BSA, 
bovine serum albumin; DMEM, Dulbecco's Modified Eagle’s medium; EDTA, 
ethylenediaminetetracetic acid; ERK, extracellular-signal regulated kinase; FBS, 
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foetal bovine serum; JNK, c-jun kinase; RAGE, receptor for advanced glycation 
endproducts; MAPK, mitogen-activated protein kinase; MG, methylglyoxal; MG-
BSA-AGES, methylglyoxal-derived bovine serum albumin AGEs; MMP, matrix 
metalloproteinase; NF-B, nuclear factor kappa B; PI3K, phosphoinositol-3 kinase; 
PKC, protein kinase C; PMSF, phenylmethylsulfonyl fluoride; p70S6K1, ribosomal 
protein 70 serine S6 kinase beta 1; ROS, reactive oxygen species; SD, standard 
deviation; SDS-PAGE, sodium dodecyl sulphate polyacrylamide gel electrophoresis; 
SPM, serum-poor medium; STAT, signal transducer and activator of transcription. 
 
1. Introduction 
Diabetes and cancer are major health problems and prevalent diseases with a globally 
increasing incidence. Generally, cancer has an increased metabolism associated with 
elevated glycolytic rates which enhance the formation of advanced glycation 
endproducts (AGEs) [1]. AGEs are a group of heterogeneous macromolecules formed 
during a non-enzymatic reaction called the Maillard reaction [2]. This Maillard 
reaction is responsible for the intermolecular cross-linking between the reactive 
carbonyl group of sugars and the nucleophilic amino group of proteins, lipids or 
nucleic acids [3, 4]. Although this glycation reaction is a non-specific biochemical 
reaction, protein modification results in altered enzyme activity [5], immunogenicity 
[6], decreases ligand binding [7], and cross-linking of extracellular matrix proteins, 
which cause stiffening [8]. Increased protein glycation has been associated with 
several age-related [9] and chronic inflammatory diseases such as cardiovascular 
diseases [10], Alzheimer’s disease [11], stroke, retinopathy [12], nephropathy [13], 
neuropathy and cancer [14]. In addition, AGE formation is often accompanied by 
increased free radical activity, which can damage cell membranes and cause gene 
mutations resulting in malignant cell transformation [15].  
The cellular effects of AGEs are mainly mediated through the receptor for advanced 
glycation endproducts (RAGE). RAGE is a 45-kDa transmembrane multi-ligand 
signal transduction receptor belonging to the immunoglobulin superfamily, which is 
highly expressed during embryonic development, especially in the brain, and then its 
expression decreases in adult tissues [16]. In pathological conditions, RAGE 
expression is induced by high glucose [17], reactive oxygen species (ROS), external 
stress, hypoxia [18], pro-inflammatory mediators and by AGE itself [17]. RAGE is 
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also over-expressed on activated immune cells [19], vascular cells [20] and cancer 
cells [21]. AGE-RAGE interactions trigger a diverse array of signalling pathways 
[22], including mitogen activated protein kinase (MAPK) such as extracellular-signal 
regulated kinase (ERK)-1/2 [20], p38 [23] and c-jun kinase (JNK), that induce the 
activation of transcription factors such as nuclear factor kappa B (NF-B) [24], 
activator protein (AP)1 and signal transducers and activators of transcription (STAT)-
3 [25]. This is accompanied by ROS production [26] and by subsequent transcription 
and changes in gene expression, which result in tumour growth through increased cell 
proliferation [27] and tumour metastasis through stimulation of cell migration and 
invasion [14]. In addition, matrix metalloproteinases (MMPs) and especially 
gelatinases (i.e. MMP-2 and MMP-9) are known to promote cancer progression with 
their central role during the invasion process as they degrade the connective tissue 
mainly composed of type I collagen (or gelatine for denatured collagen) and the 
basement membrane mainly composed of type IV collagen [28]. AGE-RAGE 
interactions also induce the activation of phosphoinositol-3 kinase (PI3K) [27], 
oncogenic Ras, protein kinase C (PKC) and members of Rho/GTPase (Cdc42 and 
Rac-1) signalling pathways, which lead to cell survival, stress responses and 
apoptosis, release of growth factors and pro-inflammatory cytokines, and motility 
with changes in cell shape, respectively [29]. 
A meta-analysis study has reported that breast cancer rates are increased by 23% for 
women who are diagnosed with type 2 diabetes [30]. Breast cancer is a heterogeneous 
disease of particular interest. It is classified into different subtypes based on 
expression of hormone (oestrogen and progesterone) receptors and on its capability to 
invade, which defines the degree of the malignancy. Much attention has been devoted 
to the most aggressive phenotype of breast cancer with the identification of the roles 
of AGEs and the increase of RAGE expression in patient’s tissues [31]. However, 
biological effects of AGEs-RAGE on breast cancer cells are poorly investigated. 
Here, in an attempt to understand the biological effects of AGEs/RAGE in breast 
cancer, we investigated the effects of methylglyoxal-derived bovine serum albumin 
AGEs (MG-BSA-AGEs) on an invasive and non-hormone-dependent breast cancer 
cell line MDA-MB-231, with regard to cell proliferation, migration and invasion. The 
signalling pathways underlying the MG-BSA-AGE-mediated effects were also 
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investigated. To determine the consequences of glycation on MDA-MB-231 cell 
functions, the biological effects of non-modified BSA were also determined.  
 
2. Materials and Methods 
2.1. Reagents 
All reagents were obtained from Sigma-Aldrich (Dorset, UK) unless mentioned 
otherwise. 
 
2.2. Preparation of MG-BSA-AGEs 
Bovine serum albumin (BSA) fraction V (10 mg/mL) was incubated with 0.1 M 
methylglyoxal (MG) in 0.1 M sodium phosphate buffer containing 3 mM sodium 
azide (pH 7.4) and left at 37°C for 72 hours. This glycated BSA was dialysed against 
distilled water to remove unbound sugars. Dialysis was performed by stirring the 
samples at 4°C with daily changes of distilled water until equilibrium was reached. 
Non-modified BSA underwent the same preparation conditions but in the absence of 
MG. The resulting MG-BSA-AGEs were characterized using a fluorescence 
spectrophotometer (Luminescence spectrometer model LS 30 from Perkin Elmer LAS 
Ltd, Buckinghamshire, UK) with emission at 420 nm after excitation at 350 nm, 
which confirmed the higher intensity of MG-BSA-AGEs than that of non-modified 
BSA. Bacterial endotoxins were removed from non-modified BSA and MG-BSA-
AGE solutions using detoxi-gel endotoxin-removing gel columns (Thermo Scientific, 
Rockford, USA). Endotoxin levels in MG-BSA-AGEs and non-modified BSA 
solutions were measured with an E-toxate kit based on the Limulus Amebocyte lysate 
assay and were found to be below the detection limit (< 0.125 EU/mL). Protein 
concentrations were determined using a Bradford-based assay (Bio-Rad Laboratories, 
Hertfordshire, UK) with BSA as a standard.  
 
2.3. Culture of MDA-MB-231 breast cancer cells 
MDA-MB-231 breast cancer cell line was obtained from American Type Culture 
Collection (Manassas, VA, USA) and cultured in complete medium composed of 
Dulbecco's Modified Eagle’s medium (DMEM) supplemented with 10% heat-
inactivated foetal bovine serum (FBS), 2 mM glutamine and antibiotics (100 g/mL 
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streptomycin, 100 IU/mL penicillin) at 37°C in a saturated air humidity/5 % CO2  
incubator.  
 
2.4. Cell proliferation assay 
MDA-MB-231 cells (2.5 × 104/mL) were seeded in complete medium in 24-well 
plates (NuncTM, Fisher Scientific, Loughborough, UK). After 4 hours of incubation to 
allow the cells to attach to the bottom of the well, the medium was changed to a 
serum-poor medium (SPM) supplemented with 2.5% FBS in the presence or absence 
of different concentrations (25 – 200 g/mL) of MG-BSA-AGEs or non-modified 
BSA. Each condition was performed in triplicate. After 72 hours of incubation, the 
cells were detached in 250 L of 0.05% trypsin / 0.02% EDTA, and each cell 
suspension was diluted in 10 mL of isotonic solution and counted using a Beckman-
Coulter counter (Buckinghamshire, UK). Cell viability was assessed using the trypan 
blue exclusion method, which stains dead cells; whereas viable cells actively exclude 
the dye. The percentage of cell viability was determined according to the following 
formula: % viability = (viable unstained cells) / (viable unstained cells + dead stained 
cells) × 100. 
 
2.5. Cell migration assay 
MDA-MB-231 cells (5 × 104/mL) were seeded in complete medium on Thermanox® 
plastic coverslips (NuncTM) in 24-well plates. After 24 hours of incubation, the cells 
reached pre-confluence on the coverslips; the culture medium was changed to SPM 
for a further 24-hour incubation. At confluence, cells were washed three times with 
sterile PBS, and each monolayer was wounded on two sides with a sterile razor blade, 
which formed two wound edges per coverslip with cell denuded areas. Dislodged 
cells and cell debris were removed with sterile PBS. The coverslips with wounded cell 
monolayers were returned to the well containing SPM with or without different 
concentrations of MG-BSA-AGEs and non-modified BSA for 24 hours of incubation. 
Each condition was performed in duplicate. At the end of the experiment, the cells 
were rinsed with PBS, fixed with 100% ethanol for 5 minutes and then left to dry at 
room temperature. The cells were stained with 0.1% methylene blue for 2 minutes and 
washed abundantly with distilled water to reveal the degree of wound recovery. Four 
pictures from the wound edge of each side were taken to assess the cell migration by 
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counting the number of the migrated cells and by measuring the distance of the cell 
migration using image J software (http://rsbweb.nih.gov/ij/index.html).  
 
2.6. Cell invasion MatrigelTM assay 
Growth-factor reduced MatrigelTM (Becton Dickinson, Oxford, UK) was diluted (1:6) 
in serum-free medium then poured onto the porous membrane of a Transwell® 24-
insert plate (NuncTM). The plate was incubated for 30 minutes to allow the gel to 
polymerise. MDA-MB-231 cells were seeded at 104 cells /100 L in SPM (in the 
upper chamber of the Transwell®) in the presence or absence of different 
concentrations of MG-BSA-AGEs or non-modified BSA (in the well corresponding to 
the lower chamber of the Transwell®). Each condition was performed in duplicate. 
After 24 hours of incubation, the non-migrated cells on the upper side of the porous 
membrane were removed using a cotton swab soaked with PBS. The cells that 
migrated across the porous membrane were fixed with 4% paraformaldehyde and then 
stained with 0.1% Giemsa stain for cell counting using a Zeiss optical microscope. 
 
2.7. Gelatine zymography 
Matrix metalloproteinase (MMP) activities in the cell-culture media that had been 
used for the cell invasion assay (as aforementioned) were measured. The medium was 
collected and centrifuged (600 g for 15 minutes at 4°C). Protein concentration was 
determined using the Bradford protein assay (Bio-Rad), and the samples (100 g of 
protein) were mixed with an equal volume of non-reducing sample buffer. The 
samples were incubated at room temperature for 10 minutes, after which they were 
subjected to electrophoresis on 7.5% sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) containing 1 mg/mL gelatine as a substrate. The gels 
were washed in re-naturation buffer (2.5% Triton X-100) for 30 minutes at room 
temperature to remove SDS and to re-nature the MMPs in the gels. The gels were then 
rinsed in activation buffer (50 mM Tris-HCl, 0.2 M NaCl, 5 mM CaCl2 and 0.02% 
Brij 35) for 30 minutes to activate the MMPs. Gels were incubated overnight at 37°C 
with fresh activation buffer and stained with 0.5% Coomassie blue R-250 for 2 hours 
at room temperature. After destaining the gels, MMP gelatinase activity was detected 
as a white band on a dark background and quantified by densitometry using Image J 
software. 
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2.8. Preparation of cell lysates and Western blot analysis 
MDA-MB-231 cells (6 × 105/2 mL) were seeded in complete medium in 6-well plates 
(NuncTM). After 48 hours of incubation, the medium was renewed with SPM for a 
further 24-hour incubation, and MG-BSA-AGEs or non-modified BSA was added for 
5, 10, 30 and 120 minutes of incubation. After washing in cold PBS, all the 
intracellular proteins were extracted after lysing the cells with 120 µL/well of ice-cold 
radioimmunoprecipitation buffer (pH 7.5) containing 25 mM Tris-HCl, 150 mM 
NaCl, 0.5% sodium deoxycholate, 0.5% SDS, 1 mM EDTA, 1 mM sodium 
orthovanadate, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1% Triton X-100 and 1 
µM leupeptin.  
For a time-course study of RAGE expression, the cells were treated with or without 
MG-BSA-AGEs or non-modified BSA for 10 minutes and 24-72 hours of incubation. 
The cells were then lysed with 80 µL/well of ice-cold buffer containing 10 mM Tris 
HCl (pH 7.4), 50 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.05% SDS, 50 mM 
sodium fluoride, 100 M sodium orthovanadate, 10 mM beta-glycerophosphate, 10 
mM sodium pyrophosphate, 100 g/mL PMSF, 3 mM benzamidine, 1 mM 
dithiothreitol, 10 M leupeptin, 5 M pepstatin A and a cocktail of protease 
inhibitors. Protein lysates (100 µg) were mixed with 2× Laemmli sample buffer, 
denatured by boiling in a water bath for 15 minutes and then centrifuged.  
To remove the cell debris, the cell lysates were centrifuged at 20,000 g for 30 minutes 
at 4°C. The amount of proteins for each sample was determined by Bio-Rad protein 
assay and was fixed at 20-50 g for equal protein loading. An equal volume of protein 
samples and 2× sample buffer were mixed in Eppendorf® tubes and then placed in the 
boiling water for 15 minutes. Samples were separated along with pre-stained 
molecular weight markers by 12% SDS-PAGE. Proteins were electroblotted onto 
nitrocellulose membranes and the membranes were blocked for 1 hour at room 
temperature in Tris-buffered saline (TBS)-Tween (pH 7.4) containing 1% BSA. 
Membranes were stained with the following primary antibodies diluted in the 
blocking buffer, overnight at 4°C on a rotating shaker: mouse monoclonal antibodies 
to phospho-extracellular signal-regulated kinase (p-ERK1/2, Tyr204 of ERK1, sc-
7976; 1:1,000 dilution), rabbit polyclonal antibodies to total ERK1/2 [C-16] (t-
ERK1/2, sc-93; 1:1,000 dilution) and mouse monoclonal antibodies to RAGE [E-1] 
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(sc-74473; 1:1,000 dilution) provided by Santa Cruz Biotechnology (Heidelberg, 
Germany) and mouse monoclonal antibodies to GAPDH [6C5] (ab8245; 1:2,000 
dilution) and to p70S6K1 [6B2] (ab119252; 1:1,000) and rabbit monoclonal 
antibodies to phospho-p70S6K1 (p-p70S6K1, Tyr412, ab78413; 1:1,000) by Abcam 
(Cambridge, UK). After washing five times for 10 minutes in TBS-Tween at room 
temperature, the membranes were stained with either rabbit anti-mouse or goat anti-
rabbit horseradish peroxidase-conjugated secondary antibodies diluted in TBS-Tween 
containing 5% de-fatted milk (1:1,000 dilution) for 1 hour at room temperature with 
continuous mixing. After a further 5 washes in TBS-Tween, proteins were visualised 
using ECL chemiluminescent detection (Amersham Biosciences, Buckinghamshire, 
UK) and analysed using GeneSnap software with Gene tool image analyser (Syngene, 
Cambridge, UK). 
 
2.9.RNA extraction and real-time RT-PCR 
MDA-MB-231 cells (6 × 105/2 mL) were seeded in complete medium in 6-well 
plates. After 4 hours of incubation, the medium was renewed with SPM in the 
presence or absence of 100 µg/mL MG-BSA-AGEs for 24-72 hours of incubation. 
Whole RNA extraction was performed using the RNeasy mini Kit (Qiagen Inc, 
Valencia, CA) in order to quantitatively monitor by real-time PCR the mRNA 
expression of human Rage (accession number AB036432) related to internal control 
house-keeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH, accession 
number DQ403057). Complementary DNA (cDNA) was produced from total RNA 
extracts via reverse transcription using Transcriptor first-strand cDNA synthesis kit 
(Roche Molecular Systems, Pleasanton, CA), and the reaction was carried out in 
Tetrad2 Thermal Cycler (Bio-Rad). The primer pair sequences used from Invitrogen 
(Life technologies, Paisley, UK) were: 5'-GGC TGG TGT TCC CAA TAA GG-3' 
and 3'-TCA CAG GTC AGG GTT ACG GTT C-5' for human Rage as described 
previously [21] and 5'-TGA TGA CAT CAA GAA GGT GAA G-3' and 3'-TCC TTG 
GAG GCC ATG TGG GCC AT-5' for human GAPDH as designed using the primer3 
software. The real-time PCR was performed using a QuantiTect Reverse 
Transcription kit containing PCR SyberGreen Master Mix (Applied Biosystems, 
Grand Island, NY) and performed on 7500 real-time PCR system (Applied 
Biosystems). For each analysis, a negative control was prepared using all the reagents 
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except the cDNA template. All the reactions were run in triplicate, and the fold-
change of expression was calculated according to delta delta Ct (ΔΔCt) method as 
follows: fold-change = 2(-ΔΔCt) with ΔΔCt = ΔCt (RAGEtreated – GAPDHtreated) – ΔCt 
(RAGEcontrol – GAPDHcontrol). 
 
2.10. Flow cytometry analysis 
MDA-MB-231 cells (6 × 105/2 mL) were seeded in complete medium in 6-well 
plates. After 48 hours of incubation, the medium was renewed with SPM for a further 
24-hour incubation, and then 100 µg/mL MG-BSA-AGEs or non-modified BSA were 
added for a 10-minute incubation. Each condition was performed in triplicate. The 
cells were washed with PBS then scraped to maintain intact the structure of the 
transmembrane RAGE protein. After centrifugation (300 g for 10 minutes), 106 cells 
were re-suspended in 20 L of PBS then 20 g/mL of mouse anti-RAGE (E-1) 
antibody or 2 g of mouse IgG1 isotype control (ab91353 from Abcam) were added. 
The mixture was then kept on ice for 45 minutes. The excess antibody was removed 
by washing the cells twice with PBS followed by centrifugation. After the second 
centrifugation, the cells were re-suspended in 20 L of PBS, and 20 g/mL of 
monoclonal anti-mouse antibody-FITC (Invitrogen, Paisley, UK) were added. The 
mixture was then kept on ice for 30 minutes. The RAGE expression level was 
measured using FACScan analysis software from FACSCalibur Flow Cytometer 
(Becton Dickinson). 
 
2.11. Kinexus phospho-protein array analysis 
MDA-MB-231 cells (6 × 105/2 mL) were seeded in complete medium in 6-well 
plates. After 48 hours of incubation, the medium was changed to SPM. After a further 
24-hour incubation, 100 g/mL MG-BSA-AGEs or non-modified BSA were added, 
and the cells which were then incubated for 10 minutes at 37°C. To determine the 
protein expression profile of signalling pathways downstream of RAGE, a phospho-
protein array analysis (Kinetworks PhosphoSite Screen, KPSS-1.3) was performed by 
Kinexus Bioinformatics (Vancouver, Canada). Protein samples (500 g) from MG-
BSA-AGE- or non-modified BSA-treated and untreated cells were extracted 
according to the manufacturer’s instructions. The samples were used for a multi-
immunoblotting assay based on SDS-polyacrylamide mini-gel electrophoresis with 
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20-lane multi-immunoblotters using different primary antibodies. Most of the multi-
immunoblotting assays were performed at least twice. Protein expressions were 
visualised by chemiluminescence and relative expression was determined by Kinexus 
and expressed in counts per minute. 
 
2.12. RAGE neutralization 
To investigate whether MG-BSA-AGEs act through RAGE, the cells were treated 
with an anti-RAGE antibody to neutralize all the RAGE receptors. Briefly, MDA-
MB-231 cells were seeded in complete medium in 24-well plates according to the 
protocols of upstream applications previously described. The medium was renewed 
with SPM, and then 20 µg/mL mouse monoclonal anti-RAGE [E-1] antibody or 20 
µg/mL IgG1, which was used as an isotype control, were added. After 1 hour of 
incubation, the cells were treated with 100 µg/mL MG-BSA-AGEs for 10 minutes or 
a 24-72-hour stimulation at 37°C followed by RNA or protein extraction for real-time 
RT-PCR and Western blotting. The cells were also eventually subjected to all 
functional cell-based assays mentioned previously. Each condition was performed in 
triplicate, and each experiment was repeated three times.  
 
2.13. Statistical analysis 
Results are expressed as the mean ± standard deviation (SD). Experimental points 
were gathered for a minimum of three independent experiments. An unpaired 
Student's t-test was used for the comparison of two groups. A value of P < 0.05 was 
considered significant. 
 
3. Results 
 
3.1. MG-BSA-AGEs increase MDA-MB-231 cell proliferation 
We first evaluated the effects of increasing concentrations of MG-BSA-AGEs and 
non-modified BSA varying between 25 g/mL and 200 g/mL on MDA-MB-231 cell 
proliferation (see Materials and Methods). We found that MG-BSA-AGEs affected 
cell number, in a dose-dependent manner, increasing then decreasing cell proliferation 
as a bell-shaped curve. A peak of stimulation (2.0-fold increase, p < 0.01) was 
attained in the presence of 50 and 100 g/mL MG-BSA-AGEs, whereas the highest 
concentration (200 g/mL) did not alter the cell growth compared with the untreated 
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cells used as control (Figure 1A). To estimate the specific effect of MG-BSA-AGEs 
on cell proliferation, non-modified BSA was also tested. Compared with the control, 
only a low concentration of BSA (50 g/mL) slightly increased cell proliferation 
(1.25-fold, p < 0.05) whereas no effect was observed with other concentrations 
(Figure 1A). Furthermore, for each condition, the percentage cell viability was 
assessed by trypan blue exclusion and revealed a high cell viability between 97% and 
85% from the control to the highest concentration of MG-BSA-AGEs or non-
modified BSA (Figure 1B).  
 
3.2. MG-BSA-AGEs increase MDA-MB-231 cell migration  
To assess the effect of MG-BSA-AGEs on the migration of the breast cancer cell line 
MDA-MB-231, the cells were subjected to the wound-healing assay followed by a 24-
hour treatment in SPM (which reduced the cell growth) with different concentrations 
(25-200 µg/mL) of MG-BSA-AGEs or non-modified BSA (Figure 2). Representative 
photomicrographs of cell migration in untreated condition used as control (Figure 
2A), or treated conditions either with 50 g/ml MG-BSA-AGEs (Figure 2B) or non-
modified BSA (Figure 2C) are shown. Compared with the control (Figures 2A and 
2D) and to non-modified BSA (Figures 2C and 2D), MG-BSA-AGEs at 
concentrations of 25-100 g/mL increased the number of migrated cells (2.0-fold, p < 
0.05, Figure 2D). MG-BSA-AGEs significantly increased the distance of cell 
migration in a dose-dependent manner with a peak at 50 µg/mL (2.0-fold increase, p < 
0.01), compared with the control (Figure 2D). No change in cell migration was 
observed with the highest concentration of MG-BSA-AGEs (Figure 2D). Although 
non-modified BSA had no effect on MDA-MB-231 cell migration at most 
concentrations, treatment with the highest concentration (200 µg/mL) resulted in a 
significant inhibition (40% decrease, p < 0.05) in the distance migrated as compared 
with the control (Figure 2D). 
 
3.3. MG-BSA-AGEs increase MDA-MB-231 cell invasion 
The invasion of the basement membrane is a critical step during tumour progression 
because the basement membrane represents the last barrier for the cancer cells to 
reach the circulatory system and to be disseminated via metastasis. The effect of MG-
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BSA-AGEs on the MDA-MB-231 cell invasion was estimated by counting the stained 
migrated cells that passed across the porous membrane after invading the Matrigel™, 
a reconstituted basement membrane (Figure 3). Representative photomicrographs of 
cell invasion in untreated condition considered as control (Figure 3A) or treated either 
with MG-BSA-AGEs (Figure 3B) or non-modified BSA (Figures 3C) are shown. 
Compared with the control (Figure 3A), MG-BSA-AGEs at 50 g/mL and 100 g/mL 
(Figure 3C) significantly increased MDA-MB-231 cell invasion (2.0-fold, p < 0.01) 
(Figure 3D). By contrast, MG-BSA-AGEs at 25 g/mL and 200 g/mL did not 
induce any significant changes in cell invasion, compared with the control. At all 
concentrations used, no effect of non-modified BSA on MDA-MB-231 cell invasion 
was observed, compared with the control (Figure 3D).  
 
3.4. MG-BSA-AGEs enhance MMP-9 activity 
Matrix metalloproteinases (MMP)-2 and MMP-9, also called gelatinases, play a 
central role in the degradation of the type IV collagen of the basement membrane, 
thus contributing to tumour invasion and metastasis. Compared with the MMP-9 
activity in untreated MDA-MB-231 cell-condition medium (control) as assessed by 
gelatine substrate zymography, treatment with 50 and 100 g/mL MG-BSA-AGEs 
significantly (p < 0.01) enhanced MMP-9 activity (1.5-fold and 2.1-fold, respectively, 
Figures 4A and 4B). A decrease in the activity of pro-MMP-9, which is the precursor 
and inactive form of MMP-9, was noticed when the cells were treated with 200 
g/mL MG-BSA-AGEs, compared with the control (Figures 4A and 4B). The activity 
of pro-MMP-2 was enhanced after treatment with MG-BSA-AGEs at all 
concentrations used; however, no active MMP-2 was observed (Figure 4). 
 
3.5. MG-BSA-AGEs increase the phosphorylation of signalling proteins  
To optimize incubation time corresponding to the maximal cell signalling induced by 
100 g/mL MG-BSA-AGEs (concentration previously shown to significantly increase 
all MDA-MB-231 cell functions), Western blotting was used to determine the 
expression levels of phospho-ERK1/2 (p-ERK1/2) in MDA-MB-231 cells treated 
with MG-BSA-AGEs for 5, 10, 30 and 120 minutes (Figure 5). MG-BSA-AGEs 
increased the phosphorylation of ERK1/2 in cells after 5 minutes of incubation 
(Figure 5). The maximum p-ERK1/2 expression level was reached at the 10-minute 
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incubation point. Expression levels of p-ERK1/2 slightly decreased after 30 minutes 
of incubation and nearly disappeared at 120-minute incubation point (Figure 5A). To 
confirm the effect of MG-BSA-AGEs on p-ERK1/2 expression level, MDA-MB-231 
cells were treated with or without 100 g/mL MG-BSA-AGEs or non-modified BSA 
for 10 minutes (Figure 5B). Compared with untreated cells (control), MG-BSA-AGE 
treatment increased the phosphorylation of ERK1/2 (1.8- and 2.8-fold increase for p-
ERK1 and p-ERK2, respectively) while no change of ERK1/2 phosphorylation was 
observed in non-modified BSA-treated cells (Figure 5B). 
A wider investigation of the downstream phosphorylated proteins of MG-BSA-
AGEs/RAGE signalling pathways was proceeded as follows: the whole cell lysates of 
untreated MDA-MB-231 cells (control, Figure 5C1) or cells treated with 100 g/mL 
MG-BSA-AGEs (Figure 5C2) and 100 g/mL non-modified BSA (Figure 5C3) were 
analysed using the phospho-protein array analysis KPSS-1.3 for 35 phospho-proteins 
including p-ERK2 (Figure 5C). Like using Western blot analysis, quantification of the 
immuno-blots showed that MG-BSA-AGEs also resulted in a 3.0-fold increase of 
ERK2 phosphorylation, which reinforced the reproducibility and the validity of the 
data (Figure 5B). MG-BSA-AGEs increased the phosphorylation of the ribosomal 
protein serine S6 kinase (p70S6K)-beta 1 (25.4-fold increase), the signal transducer 
and activator of transcription (STAT)-3 (8.0-fold increase), MAPK p38 and 
glycogene synthase-serine kinase (GSK)-3 (5.6-fold and 3.2-fold, respectively), and 
MAPK/ERK protein-serine kinase 1/2 (MKK1/2, 4.6-fold increase), compared with 
untreated cells (Figure 5C4). Furthermore, the phosphorylation of c-Jun and its kinase 
JNK was increased (2.0-fold) in MG-BSA-AGE-treated cells as compared with 
untreated cells (control). The phosphorylation of the tumour-suppressor protein 
retinoblastoma-associated protein-1 (pRb) was also increased (2.6-fold) in MG-BSA-
AGE-treated cells. Cell treatment with 100 g/mL non-modified BSA had no 
significant effects on the phosphorylation of the proteins studied, compared with the 
control (Figure 5C). 
 
3.6. MG-BSA-AGEs up-regulate RAGE expression 
A time-course of expression levels of RAGE in MDA-MB-231 cells following 
treatment with 100 g/mL MG-BSA-AGEs was established using Western blotting 
and real-time RT-PCR. MG-BSA-AGEs treatment led to up-regulation of RAGE 
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protein levels in a time-dependent manner (Figure 6A). Within 10 minutes, RAGE 
expression levels increased in MG-BSA-AGE-treated cells, compared with the basal 
level of RAGE expressed in untreated cells (Figure 6A). This data was further 
confirmed using flow cytometry analysis (Figure 6B). Western blot analysis revealed 
a peak of RAGE protein expression levels (3.0-fold increase, p < 0.0001) after 24 
hours of incubation with MG-BSA-AGEs, whereas a peak of RAGE mRNA 
expression (5.0-fold increase, p < 0.001) was noticed after 48 hours of incubation 
(Figure 6C). After 72 hours of incubation with MG-BSA-AGEs, there was not 
significant difference in RAGE transcript and protein levels between MG-BSA-AGEs 
treated and untreated cells (Figure 6). 
 
3.7. MG-BSA-AGEs stimulate MDA-MB-231 cells through RAGE 
To check whether MG-BSA-AGEs stimulated MDA-MB-231 cells through their 
major receptor RAGE, the cells were pre-treated with either a neutralizing RAGE 
antibody to block all the RAGE receptors or with an isotype control IgG1 used as a 
negative control (Figure 7). RAGE neutralization process was applied to verify 
whether MG-BSA-AGEs induce the increased phosphorylation of signalling proteins 
such as ERK1/2 (the key protein of signalling pathways) and p70S6K1 (the most 
over-phosphorylated protein induced by MG-BSA-AGEs) through RAGE. The 
isotype control IgG1 did not affect ERK1/2 phosphorylation induced by MG-BSA-
AGEs, compared with the basal expression level of p-ERK1/2 in untreated cells used 
as control (Figure 7A). However, 100 g/mL BSA-AGEs did not enhance ERK1/2 
phosphorylation in the cells pre-treated with neutralizing RAGE antibody (Figure 
7A). In addition, the protein array analysis previously described was confirmed by a 
similar concomitant increase of p70S6K1 phosphorylation induced by MG-BSA-
AGEs even in IgG1-treated cells, compared with the control (Figure 7B). The 
blockade of RAGE completely inhibited MG-BSA-AGE-induced p70S6K1 
phosphorylation (Figure 7B). On the cell function aspects, the addition of MG-BSA-
AGEs to IgG1-pretreated cells induced a significant increase in cell proliferation (1.8-
fold, p < 0.001, Figure 7C), cell migration (2.0-fold, p < 0.05, Figure 7D) and cell 
invasion (1.6-fold, p < 0.05, Figure 7E) as compared with the untreated cells 
(control). However, the addition of MG-BSA-AGEs to cells pre-treated with anti-
RAGE antibody did not change the cellular processes as compared with the control. 
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Altogether, MG-BSA-AGEs lost their biological effects after the blockade of RAGE, 
demonstrating that MG-BSA-AGEs act through RAGE.  
 
4. Discussion 
Diabetes and cancer are a cause for concern because of the high incidence of these 
diseases in Western countries and, more recently, in developing countries. A growing 
body of epidemiological evidence suggests a molecular link between diabetes and 
breast cancer [31, 32]. In diabetic patients, the most circulating and abundant 
advanced glycation endproducts (AGEs)-derived protein is serum glycated albumin 
[33]. In patients with breast cancer, serum concentrations of AGEs were higher than 
in healthy controls [32]. To date, the biological effects of glycated albumin on human 
breast cancer cells have been poorly described.  
Here, we have shown that MG-BSA-derived AGEs increase the proliferation, 
migration and invasion (associated with an enhancement of MMP-9 gelatinase 
activity) of the invasive and non-hormone-dependent cell line MDA-MB-231 in vitro. 
Furthermore, MG-BSA-AGEs increase expression of RAGE and phosphorylation of 
ERK1/2 and other key signalling proteins such as p70S6K1. In addition, the blockade 
of RAGE using a neutralizing RAGE antibody removes all these MG-BSA-AGE 
effects. By contrast, non-modified BSA showed little biological effects on MDA-MB-
231 cells. These new findings suggest that AGEs might contribute to the development 
and progression of invasive breast cancer. RAGE over-expression and the 
phosphorylation of key proteins induced by AGEs might represent promising targets 
for drug therapy to treat diabetic patients with breast cancer. 
MG-BSA-AGEs increased MDA-MB-231 cell proliferation, migration and invasion, 
in a dose-dependent manner as shown by a bell-shaped curve, while non-modified 
BSA had no biological effects, except a slight stimulatory effect on cell proliferation 
at 50 g/mL and an inhibitory effect on cell migration at 200 g/mL. This slight pro-
mitogenic effect of non-modified BSA is correlated with the induction of ERK1/2 
phosphorylation observed at short incubation time (10 minutes) at the same 
concentration (50 g/mL) in our pilot studies (data not shown), whereas no increase 
in phosphorylation of ERK1/2 was induced by 100 g/mL of non-modified BSA. The 
pro-mitogenic effect of native BSA was also reported by Chung and colleagues using 
tubular epithelial cells in similar conditions [34]. This slight positive effect might be 
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attributed to a traceable amount of AGEs reported to be observed in native albumin, 
the most common serum protein known to be readily glycated in vivo. Indeed, native 
albumin is modified by 0.3 mol/mol of sugars and this is likely to be by glucose, the 
major metabolic sugar [35]. However, modification by other sugars such as 
methylglyoxal cannot be ruled out and may contribute towards AGE formation on 
native albumin. In contrast, the inhibitory effect of high concentration of native BSA 
on cell migration may be caused by the inhibition of cell adhesion, which plays a 
critical role in cell motility, due to the high adsorption of BSA between the culture 
medium and the solid surface as it was previously reported [36]. Here, bell-shaped 
curves representing the MDA-MB-231 cell response to MG-BSA-AGE biological 
effects are indicative of a bivalent bridging mechanism describing the 
dimerization/oligomerization of specific cell-surface receptors after binding with the 
ligand [37]. Indeed, throughout this present study, the maximal cell response was 
obtained with 50 and 100 g/mL MG-BSA-AGEs, which might correspond to the 
optimal oligomerization of the AGE receptor such as RAGE to induce the maximal 
signalling. Therefore, the loss of the cell response seen at the highest concentration 
(i.e. 200 g/mL) of MG-BSA-AGEs may be due to impediment of RAGE 
oligomerization. Furthermore, using an epitope-defined monoclonal antibody that 
specifically recognises receptor oligomerization, Xu and colleagues demonstrated the 
importance of RAGE oligomerization for the formation of active signalling 
complexes [38]. In addition, a recent study provides insights into the factors that 
influence AGEs-RAGE binding including glycation agent like methylglyoxal and the 
RAGE structure [39]. Indurthi et al. (2012) used 1 and 5 mM methylglyoxal to 
modify BSA respectively; they demonstrated that higher concentration of 
methylglyoxal produced more AGEs, which showed increased binding affinity to 
RAGE. They suggested that higher glycation generate more potential binding sites for 
RAGE in the protein surface [39]. In the present study, we applied 100 mM 
methylglyoxal to generate MG-BSA-AGEs to ensure a high binding potential to 
RAGE. Using siRNA technology, RAGE has been shown to play a critical role in the 
growth of human breast cancer cell lines, including MDA-MB-231 [21]. Most studies 
on BSA-AGEs, including this investigation, compare the biological effects of MG-
BSA-AGEs with native non-modified BSA, which in agreement with previous work 
show no biological effects or little effects at the concentrations or experimental 
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conditions used [40]. Indeed, native globular BSA even bound to the cell surface 
rarely triggers specific transduction signalling unlike BSA-AGEs [41, 42]. Therefore, 
the mode of action of MG-BSA-AGEs is dependent on pathways mediated via RAGE 
rather than BSA-mediated pathways. 
In this present study, we also showed that the enhancement of MDA-MB-231 cell 
invasive capacity induced by MG-BSA-AGEs was associated with MMP-9 gelatinase 
activity without changing MMP-2 gelatinase activity. Non-modified BSA had no 
effect on both MMP activities. Invasion and metastasis are key cell events resulting in 
tumour progression and are the hallmarks of cancer malignancy. During metastasis, 
cancer cells degrade the matrix by production and secretion of MMPs. MMPs 
facilitate cell migration and invasion across the connective tissue and the basement 
membrane to reach the blood circulation which is the main route of tumour 
dissemination towards vascularized organs. A study has shown that incubating human 
lung adenocarcinoma cell with glyceraldehyde-AGEs for 48 hours, promoted cell 
migration and invasion across Matrigel™ with enhancement of MMP-2 activity but 
not MMP-2 mRNA [43]. Recently, Noh and colleagues reported MMP-2 from body 
fluid as a putative biomarker in metastatic breast cancer [44]. However, Hallett and 
colleagues targeted MMP-9 mRNA in a mouse model using anti-MMP-9 DNAzyme 
transfected into MDA-MB-231 cells, and they reported a decrease of breast cancer 
and confirmed the key role of MMP-9 in breast cancer metastasis [45]. Furthermore, 
using a murine macrophage cell line, it has been shown that AGEs have regulated 
MMP-9 production via RAGE, which is in agreement with our present work, and was 
associated with activation of ERK1/2, p38 MAPK and NF-B [46]. Therefore, our 
results suggest that MG-BSA-AGEs might promote breast tumour progression by 
increasing cancer cell migration, invasion and MMP-9 activity.  
During MDA-MB-231 cell treatment with MG-BSA-AGEs, the cells displayed a 
maximum RAGE up-regulation after 24 hours of incubation. Recently, Shi and 
colleagues reported that AGEs up-regulate RAGE expression in various tissues, 
reaching a maximum after a 24-hour treatment, which facilitates the AGE-RAGE 
response by forming a positive feedback loop [41]. This suggests that RAGE up-
regulation induced by MG-BSA-AGEs may contribute to the increased cellular 
response assessed as proliferation, migration and invasion. In addition, in endothelial 
progenitor cells, BSA-AGE-induced RAGE up-regulation has been demonstrated to 
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be ERK1/2 and p38 MAPK-dependent but not mediated by JNK MAPK [47]. We 
observed the peak up-regulation of RAGE mRNA expression level after 48 hours of 
treatment with MG-BSA-AGEs, whereas the protein expression level was lower, 
indicating a negative-feedback loop of the translational regulatory system of RAGE 
protein expression. To confirm this hypothesis, additional studies might be of interest 
on the key factors regulating the translational system of RAGE protein expression 
such as, microRNA and nuclear transcription factors p65/50 NF-B and Sp-1/ER, 
previously demonstrated to be involved in this regulatory process [48]. 
p-ERK1/2 is a phospho-protein widely known to play a central role in most cellular 
responses including cell proliferation, migration and invasion. We found that the 
optimal signal for MG-BSA-AGE-induced p-ERK1/2 expression in MDA-MB-231 
cell line was obtained after 10-minute treatment. Similar early phosphorylation of 
ERK1/2 was reported to be induced by BSA-AGEs in various cell types [34]. We 
demonstrated that MG-BSA-AGEs enhanced phosphorylation of ERK1/2 and 
stimulated all cellular functions through RAGE, as these processes were attenuated 
after neutralization of the receptor using a specific monoclonal antibody. Thus, this 
result eliminates the involvement of other AGE receptors such as CD36, scavenger 
receptors class A type II, class B type I and AGE receptors 1, 2 and 3, which are 
mainly implicated in the detoxification of AGEs rather than in signalling processes 
[49].  
Although 100 g/mL non-modified BSA did not change the phospho-proteome 
profile of MDA-MB-231 cells compared to untreated cells, at a similar concentration, 
MG-BSA-AGEs concomitantly increased the phosphorylation of p70S6K1, STAT-3, 
p38 MAPK, GSK-3 and MKK1/2. The p70S6K1 has been demonstrated to play a 
central role in tumour growth by regulating pro-angiogenic effects and protein 
synthesis of insulin [50, 51]. In addition, targeting p70S6K1 gene expression by 
micro-RNA 145 expression has been reported to inhibit tumour growth [52]. 
Constitutively active STAT proteins, which are critical in the regulation of cell cycle 
and cell growth, are found in various types of tumours including breast cancer [53]. 
Previous studies have reported p38 MAPK as a central kinase in a common 
intracellular signalling pathway that plays an essential role in human breast cancer 
cell migration and invasion by modulating the expression and activity of MMPs [54]. 
Furthermore, several lines of evidences suggest a link between p38 MAPK activation 
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and MMP-9 expression [55]. In some reports, the use of pharmacological inhibitors of 
GSK-3 and of p38 MAPK, which are proteins with increased phosphorylation 
observed in our study, in MDA-MB-231 cells and in a model mouse of breast cancer 
demonstrated the key requirement of these proteins in breast cancer development [56, 
57]. Here, we also showed that MG-BSA-AGE-induced p70S6K1 over-
phosphorylation was prevented after RAGE neutralization, which further removes all 
the biological effects of MG-BSA-AGEs-induced MDA-MB-231 cell proliferation, 
migration and invasion. Thus, altogether, targeting either the expression of phospho-
proteins aforementioned such as p70S6K1 or targeting RAGE expression might 
prevent the progression and development of breast cancer in diabetic patients.  
 
In conclusion, as a consequence of BSA glycation, this study demonstrated the 
stimulatory effects of MG-BSA-AGEs on cell proliferation, migration and invasion 
(with an enhancement of MMP-9 activity) through RAGE, in an invasive and non-
hormone-dependent breast cancer cell line MDA-MB-231. Among the phospho-
proteins involved in MG-BSA-AGE-induced signalling pathways, we also highlighted 
a concomitant increase in the phosphorylation of p70S6K1, which might be a new 
biomarker of the invasive subtype of the breast cancer and a promising target drug 
like RAGE to fight against breast cancer in diabetic patients. 
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Figure legends 
Figure 1: Effect of MG-BSA-AGEs and non-modified BSA on (A) the 
proliferation and (B) the viability of breast cancer MDA-MB-231 cells. Cells were 
treated for 72 hours of incubation with 25-200 g/mL MG-BSA-AGEs or non-
modified BSA. Cell number (A) and cell viability (B) were determined using an 
automatic cell counter and the trypan blue exclusion method, respectively. Control 
indicates non-treated cells. Results are presented as mean ± SD of three independent 
experiments. (*), (**) and (***) signify a statistically significant difference (p < 0.05, 
p < 0.01 and p < 0.001), compared with the control. 
 
Figure 2: Effect of MG-BSA-AGEs and non-modified BSA on the migration of 
breast cancer MDA-MB-231 cells. Representative photomicrographs (×400 
magnification) showing MDA-MB-231 cell migration measured from the wound edge 
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(indicated by the arrow) after 24 hours of incubation in (A) non-treated (control) or 
(B) 50 μg/mL MG-BSA-AGE-treated or (C) non-modified BSA-treated cells. Scale 
bar = 100 m. (D) Quantification of the number of migrated cells (black bars) and the 
distance of migration (grey bars) of MDA-MB-231 cells treated in the aforementioned 
conditions. Results are presented as mean ± SD of three independent experiments. 
Results are presented as mean ± SD of three independent experiments. (*) and (**) 
signify a statistically significant difference (p < 0.05 and p < 0.01), compared with the 
control. 
 
Figure 3: Effect of MG-BSA-AGEs and non-modified BSA on the invasion of 
breast cancer MDA-MB-231 cells. Representative photomicrographs (×100 
magnification) of (A) untreated MDA-MB-231 cells (control), (B) cells treated with 
100 g/mL MG-BSA-AGEs and (C) non-modified BSA in the MatrigelTM invasion 
assay. Stimulated cells which had invaded the MatrigelTM (a reconstituted basement 
membrane) and migrated across the porous membrane were stained with Giemsa dye 
for counting. (D) Quantification of number of invaded MDA-MB-231 cells after 
treatment with 25-200 g/mL MG-BSA-AGEs or non-modified BSA, compared with 
the control. Results are presented as mean ± SD of three independent experiments. 
(**) signifies a statistically significant difference (p < 0.01), compared with the 
control. 
 
Figure 4: Effect of MG-BSA-AGEs on MMP-9 and MMP-2 activities produced 
by breast cancer MDA-MB-231 cells during the MatrigelTM invasion assay. (A) 
Representative gelatine zymograhic analysis showing the activity of MMP-9 and 
MMP-2 from cell conditioned media collected after Matrigel invasion assay by MDA-
MB-231 cells treated with 25-100 g/mL MG-BSA-AGEs, compared with untreated 
cell-condition medium (control, c). The gels revealed gelatinolytic activities of pro- 
and active MMP-9 and pro-MMP-2. (B) Quantitative gelatinolytic activity of pro- and 
active MMP-9 and (C) pro-MMP-2 expressed as relative activity, which was 
calculated as a ratio of the control. Results are presented as mean ± SD of four 
independent experiments. (*), (**) and (***) signify a statistically significant 
difference (p < 0.05, p < 0.01 and p < 0.001), compared with the control. 
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Figure 5: Effect of MG-BSA-AGEs on the phosphorylation of signalling proteins 
in MDA-MB-231 cells. (A) Representative Western blot analysis showing 
phosphorylation of ERK1/2 (p-ERK1/2) induced by 100 μg/mL MG-BSA-AGEs after 
different incubation times varying from 5 to 120 minutes, compared with untreated 
cells (control). (B) Representative Western blot analysis (B1) showing the effect of 
100 g/mL MG-BSA-AGEs or non-modified BSA on the phosphorylation of ERK1/2 
expression, compared with the control. (B2) Relative phosphorylation of ERK1/2 
calculated as a ratio to the total ERK1/2 (t-ERK1/2), the loading control. Results are 
presented as mean ± SD of three independent experiments. (**) signifies a statistically 
significant difference (p < 0.01), compared with the control. (C) Multi-
immunoblotting of 35 phospho-proteins expressed in untreated (C1) MDA-MB-231 
cells, cells treated with 100 g/mL MG-BSA-AGEs (C2) or cells treated with non-
modified BSA (C3) after 10 minutes of incubation. (C4) The bar graph shows the 
relative expression of the relevant phospho-proteins expressed in counts per minute 
and calculated as a ratio to the untreated cells (control). 
 
 
Figure 6: Time-course of RAGE protein and mRNA expression in breast cancer 
MDA-MB-231 cells treated with MG-BSA-AGEs. (A) Representative Western blot 
analysis (A1) showing the effect of 100 μg/mL MG-BSA-AGEs on RAGE expression 
in MDA-MB-231 cells after incubation for 10 minutes or 24, 48 or 72 hours, 
compared with untreated cells (control). Bar graph (A2) showing the relative 
expression of RAGE calculated as a ratio to GAPDH expression, the loading control. 
(B) Representative FACS analysis (B1) of the RAGE up-regulation induced by 100 
g/mL MG-BSA-AGEs after 10 minutes of incubation. IgG1 was used as an isotype 
control. Bar graph (B2) indicating the quantification of the percentage of RAGE-
positive cells calculated as a ratio to isotype control. (C) Relative expression of 
RAGE mRNA as determined using real-time PCR analysis. Results are presented as 
mean ± SD of three independent experiments. (*) and (**) signify a statistically 
significant difference (p < 0.05 and p < 0.01), compared with the control. 
 
Figure 7: RAGE mediates the effects of MG-BSA-AGEs in breast cancer MDA-
MB-231 cells. Representative Western blot analysis showing the loss of MG-BSA-
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AGE-induced phosphorylation of (A) ERK1/2 and (B) p70S6K1 after the blockade of 
RAGE by an anti-RAGE antibody, compared with untreated cells (control) and an 
isotype control IgG1. Bar graphs show the relative expression levels of (A2) p-
ERK1/2 and (B2) p-p70S6K1 calculated as a ratio to the total ERK1/2 (t-ERK1/2) and 
total p70S6K1 (t-p70S6K1), the respective loading controls. Loss of MG-BSA-AGE-
induced (C) cell proliferation, (D) migration and (E) invasion after RAGE blockade 
using a neutralizing blocking anti-RAGE antibody, compared with untreated cells 
(control) and an isotype control IgG1. Results are presented as mean ± SD of three 
independent experiments. (*) and (**) signify a statistically significant difference (p < 
0.05 and p < 0.01), compared with the control. 
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